Aug 15
Opportunity
Access to clinical trials may be limited depending upon the participant’s circumstance. Providing support services (e.g., transportation assistance) may help to eliminate logistical barriers to participation.
Considerations to Help Action the Opportunity
- Incorporate input from participants, care partners and sites to proactively develop a plan to implement support services
- Partner with investigative sites to understand if support service(s) is suitable for the clinical setting and their participants
- Define reimbursement options, including how and what to reimburse, tailoring services to the sites’ and patients’ needs, such as:
- Accessibility supports
- Transportation assistance
- Accommodation assistance
- Care of dependents
- Food
- Out-of-pocket
- Consider how to provide reimbursement in a timely manner
- Identify a single point-of-contact for participant coordination on all relevant support services, including navigating insurance where applicable
- Consider extending hours of operation for participants to attend in evenings or weekends
- Understand the timing of assessments to help minimize participant burden, such as reducing the need to fast all day and facilitating out-of-hours collections or windows for collection (e.g., lab samples testing over the weekend or an allowance that these can be stored over the weekend to facilitate collection of samples on a Friday)
Value and Potential Benefits
- Allows greater access to clinical trials and helps further support patients to remain enrolled
- Maximizes flexibility in the type of study visits available for participant with less logistic burden
- Increases convenience to participate regardless of participant’s life circumstances (e.g., barriers to trial participation due to health status, financial background, logistical burdens, mental blockades, and insecurities)
Related Blog Posts
Are Pragmatic Trials The Patient Recruitment Solution We’ve Been Looking For?
The age-old problem for clinical research has been the ability to recruit patients. Many clinical research professionals have tried to crack this nut, whether with technology or partnerships or both. Let’s not forget the height of DCTs during the pandemic, which served their purpose but appear to have lost luster in the last few years.…
Solving the Clinical Trial Data Problem
In a new LinkedIn article, Janice Chang, CEO of TransCelerate, and Nicholas Brooke, CEO of The Synergist & PFMD, outline how efforts like the Clinical Trial Data Network, supported by TransCelerate through technical expertise and industry-vetted solutions from our Digital Data Flow initiative, aim to make clinical trial information more structured, connected, and accessible across…
The Clinical Trial Enterprise: Can AI Fix It?
Artificial Intelligence (AI) is reasonably well established in discovery and preclinical research, with success in areas such as target identification and molecular modeling. However, in clinical development, adoption has been fragmented and challenging to embed across the lifecycle. Read the full article by Rob DiCicco from Drug Discovery News here.